Neurology & Neurotherapeutics - NE Outside Agreements

Medicine & Life Sciences

1. Multiple Sclerosis 100%
2. Tuberous Sclerosis 40%
3. Natalizumab 29%
4. Holoprosencephaly 26%
5. Therapeutics 24%
6. Cerebral Palsy 20%
7. Central Nervous System 18%
8. Neuromyelitis Optica 18%
9. T-Lymphocytes 18%
10. Child 17%
11. Central Nervous System Diseases 16%
12. Autoimmune Diseases of the Nervous System 16%
13. Relapsing-Remitting Multiple Sclerosis 16%
14. Autoimmune Experimental Encephalomyelitis 15%
15. Glioblastoma 14%
16. abobotulinumtoxinA 14%
17. Glatiramer Acetate 14%
18. Chronic Progressive Multiple Sclerosis 13%
19. B-Lymphocytes 13%
20. Hydroxymethylglutaryl-CoA Reductase Inhibitors 12%
21. ErbB Receptors 11%
22. Epilepsy 11%
23. epidermal growth factor receptor VIII 10%
24. Astrocytoma 10%
25. Brain 10%
26. Carbamazepine 10%
27. Autoimmunity 9%
28. Mutation 9%
29. Safety 9%
30. Everolimus 8%
31. Pharmaceutical Preparations 8%
32. siponimod 8%
33. Phenotype 8%
34. Cerebrospinal Fluid 8%
35. Progressive Multifocal Leukoencephalopathy 8%
36. Seizures 8%
37. Genes 8%
38. Angiomyolipoma 8%
39. Neoplasms 7%
40. Clinical Trials 7%
41. Glioma 7%
42. Interferon-beta 7%
43. Placebos 7%
44. Rituximab 7%
45. quinpramine 7%
46. Type A Botulinum Toxins 6%
47. Fingolimod Hydrochloride 6%
48. ocrelizumab 6%
49. Pediatrics 6%
50. Demyelinating Diseases 6%
51. Somatosensory Evoked Potentials 6%
52. Immunosuppressive Agents 6%
53. Acute Disseminated Encephalomyelitis 6%
54. Incidence 6%
55. Alemtuzumab 6%
56. Mitoxantrone 5%
57. Dimethyl Fumarate 5%
58. N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide 5%
59. Injections 5%
60. Receptor-Interacting Protein Serine-Threonine Kinases 5%
61. teriflunomide 5%
62. Aquaporin 4 5%
63. Neuroimaging 5%
64. Interferons 5%
65. Oligodendrocyte-Myelin Glycoprotein 5%
66. 4-dichlorobenzene 5%
67. Monoclonal Antibodies 5%
68. Recurrence 5%
69. Systematic Reviews 5%
70. Cladribine 5%
71. Autoimmune Diseases 5%